CK Life Sciences International Holdings (HKSE:00775) COGS-to-Revenue : 0.69 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is CK Life Sciences International Holdings COGS-to-Revenue?

CK Life Sciences International Holdings's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$1,906 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$2,744 Mil.

CK Life Sciences International Holdings's COGS to Revenue for the six months ended in Dec. 2023 was 0.69.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CK Life Sciences International Holdings's Gross Margin % for the six months ended in Dec. 2023 was 30.53%.

CK Life Sciences International Holdings COGS-to-Revenue Historical Data

The historical data trend for CK Life Sciences International Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CK Life Sciences International Holdings COGS-to-Revenue Chart

CK Life Sciences International Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.68

0.72

0.70

0.69

CK Life Sciences International Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.71	0.69	0.69	0.69	0.69

CK Life Sciences International Holdings COGS-to-Revenue Calculation

CK Life Sciences International Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3685.525	/	5322.733
	=	0.69

CK Life Sciences International Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1905.869	/	2743.605
	=	0.69

CK Life Sciences International Holdings (HKSE:00775) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CK Life Sciences International Holdings's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1905.869 / 2743.605
	=	30.53 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CK Life Sciences International Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CK Life Sciences International Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CK Life Sciences International Holdings (HKSE:00775) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CK Life Sciences International Holdings Inc (HKSE:00775) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

LSI:Germany

Address

2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG

Website

https://www.ck-lifesciences.com

CK Life Sciences International Holdings Inc is a biotechnology company engaged in the research & development, commercialization, and sale of health and agricultural-related products. Products developed by CK Life Sciences are categorized into the areas of human health and environmental sustainability. The company operates three core businesses, including agriculture, nutraceutical, and pharmaceutical. Its overall product portfolio involves a presence that spans North America and the Asia Pacific. The company uses mergers and acquisitions when it identifies attractive market opportunities.

CK Life Sciences International Holdings (HKSE:00775) Headlines

No Headlines